ArticleNature medicine2019
A clonal expression biomarker associates with lung cancer mortality.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 77 papers.
0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
4.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 129 citations in OpenAlex.
- A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma.Immuno-oncology technology · 2026Article
- Gene Expression Clustering of Lung Adenocarcinoma Tumors as a Prognosis Tool to Infer Progression-Free Survival.JTO clinical and research reports · 2026Article
- Charting intratumor heterogeneity from bench to bedside.Nature cancer · 2026Review
- Mitochondrial DNA mutations drive tumor heterogeneity in papillary thyroid carcinoma.iScience · 2026Article
- Single-cell and multi-omics integration delineates the landscape of gene-wise intratumor heterogeneity and identifies prognostic biomarkers for immunotherapy in non-small cell lung cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma.Cell reports. Medicine · 2026Article
- Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R.Cell communication and signaling : CCS · 2026Article
- A guide to transcriptomic deconvolution in cancer.Nature reviews. Cancer · 2026Review
- Integrated Multi-Omics Analysis Constructs an Intratumoral Heterogeneity-Corrected Prognostic Signature for Cervical Cancer.International journal of general medicine · 2026Article
- Tracing the evolution of single-cell 3D genomes in Kras-driven cancers.Nature genetics · 2025Article
- Current trends in single-cell RNA sequencing applications in diabetes mellitus.FEBS open bio · 2025Review
- High-resolution spatial mapping of cell state and lineage dynamics in vivo with PEtracer.Science (New York, N.Y.) · 2025Article
- Expansion of a circulating Ki67-positive effector T-cell population following combined PD-1 and CTLA-4 blockade for melanoma is predictive of treatment response.Journal for immunotherapy of cancer · 2025Article
- Dual-Targeting of ATOX1 and ROCK1: A Potent Strategy to Potentiate the Inhibition of Lung Adenocarcinoma Proliferation.Cancers · 2025Article
- Transforming Population Health Screening for Atherosclerotic Cardiovascular Disease with AI-Enhanced ECG Analytics: Opportunities and Challenges.Current atherosclerosis reports · 2025Review
- Epigenetic regulators combined with tumour immunotherapy: current status and perspectives.Clinical epigenetics · 2025Review
- Review
- Article
- Integrins as Key Mediators of Metastasis.International journal of molecular sciences · 2025Review
- Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
36 authors at 12 institutions in 7 countries.
Dhruva Biswas *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK.
Nicolai J Birkbak *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK. nbirkbak@clin.au.dk.ORCID http://orcid.org/0000-0003-1613-9587
Rachel RosenthalCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK.
Crispin T HileyCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK.
Emilia L LimCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK.
Krisztian PappDepartment of Physics of Complex Systems, ELTE Eötvös Loránd University, Budapest, Hungary.ORCID http://orcid.org/0000-0003-0619-8233
Stefan BoeingBioinformatics and Biostatistics, The Francis Crick Institute, London, UK.
Marcin KrzystanekDanish Cancer Society Research Center, Copenhagen, Denmark.
Dijana DjureinovicDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Linnea La FleurDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Maria GrecoGenomics Equipment Park, The Francis Crick Institute, London, UK.
Balázs DömeDepartment of Tumor Biology, National Korányi Institute of Pulmonology, Semmelweis University, Budapest, Hungary.
János FillingerDepartment of Pathology, National Korányi Institute of Pulmonology, Semmelweis University, Budapest, Hungary.
Hans BrunnströmLund University, Laboratory Medicine Region Skåne, Department of Clinical Sciences Lund, Pathology, Lund, Sweden.ORCID http://orcid.org/0000-0001-7402-138X
Yin WuCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK.
David A MooreDepartment of Pathology, UCL Cancer Institute, London, UK.
Marcin SkrzypskiCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK.
Christopher AbboshCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK.
Kevin LitchfieldCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Maise Al BakirCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Thomas B K WatkinsCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Selvaraju VeeriahCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK.
Gareth A WilsonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK.
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK.
Judit MoldvayDepartment of Tumor Biology, National Korányi Institute of Pulmonology, Semmelweis University, Budapest, Hungary.
Johan BotlingDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Patrick MickeDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Allan HackshawCancer Research UK & University College London Cancer Trials Centre, University College London, London, UK.
Jiri BartekDanish Cancer Society Research Center, Copenhagen, Denmark.
Istvan CsabaiDepartment of Physics of Complex Systems, ELTE Eötvös Loránd University, Budapest, Hungary.
Zoltan SzallasiDanish Cancer Society Research Center, Copenhagen, Denmark.
Javier HerreroBill Lyons Informatics Centre, University College London Cancer Institute, Paul O'Gorman Building, London, UK.ORCID http://orcid.org/0000-0001-7313-717X
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.ORCID http://orcid.org/0000-0001-9537-4045
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK. charles.swanton@crick.ac.uk.ORCID http://orcid.org/0000-0002-4299-3018
TRACERx Consortium
The Francis Crick Institute · GBCancer Research UK · GBSemmelweis University · HUUppsala University · SEEötvös Loránd University · HUAarhus University · DKCRUK Lung Cancer Centre of Excellence · GBDanish Cancer Society · DKHoward Hughes Medical Institute · USKarolinska Institutet · SELondon Cancer · GBLund University · SE
Funding
Arthritis Research UK FC001169Arthritis Research UK FC001202Cancer Research UK 17786Cancer Research UK 19310Cancer Research UK 20265Cancer Research UK 20466Cancer Research UK 21999Cancer Research UK 22246Cancer Research UK 24956Cancer Research UK 25253Cancer Research UK 28990Cancer Research UK 30025Cancer Research UK FC001169Medical Research Council FC001169Medical Research Council MC_UP_1203/1Medical Research Council MR/M009033/1Medical Research Council MR/P014712/1Wellcome TrustWellcome Trust 211179Wellcome Trust FC001169
Abstract
An aim of molecular biomarkers is to stratify patients with cancer into disease subtypes predictive of outcome, improving diagnostic precision beyond clinical descriptors such as tumor stage
Indexed as
PrognosisAgedBiomarkers, TumorClonal EvolutionDisease-Free SurvivalDNA Copy Number VariationsExomeExome SequencingFemaleGene Expression Regulation, NeoplasticGenetic HeterogeneityHumansLung NeoplasmsMaleRisk FactorsTranscriptomeBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.